Continued mechanistic studies and examination of pharmacological Smpd1 inhibitors in the psap KO and other sphingolipidosis models could shed further light on the feasibility of this approach for targeted sphingolipidosis therapy. This evidence concerns the gene SMPD1 and sphingolipidosis.